Roche (RHHBY)'s Perjeta on US Fast-Track for Early Breast Cancer
7/2/2013 6:32:13 AM
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
Roche's Perjeta is one of the first drugs to take advantage of a new regulatory pathway in the US that is designed to get new drugs for early-stage breast cancer to market quicker.
Perjeta (pertuzumab) has been granted priority review by the FDA for use before surgery (neoadjuvant treatment) in women with HER2-positive breast cancer, setting it up for approval in the new indication by the end of October 2013.
Help employers find you! Check out all the jobs and post your resume.
comments powered by